Pathogenesis and Management of Cancer-Associated Hypercalcaemia

  • S. H. Ralston


Hypercalcaemia is the most common metabolic complication of malignant disease, occurring in about 5%–10% of cancer patients overall (Fisken et al. 1980). Although hypercalcaemia can occur with virtually any tumour, some cancers cause hypercalcaemia more frequently than others: squamous cancers and uro-epithelial cancers, for example, are common causes of hypercalcaemia, as are breast cancers and myeloma. Conversely, adenocarcinomas of the intestine seldom cause hypercalcaemia (Mundy and Martin 1982). These differences are interesting in that they reflect the ability of some tumours to release humoral factors which cause hypercalcaemia by their effects at regulatory sites of calcium homeostasis in bone, intestine and kidney.


Gallium Nitrate Humoral Hypercalcemia Tumour necrosIs Factor Etidronate Disodium Renal Tubular Calcium Reabsorption 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adami S, Bolzicci GP, Rizzo A et al. (1987) The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcaemia of malignancy. Bone Miner 2:395–404PubMedGoogle Scholar
  2. Anggard E, Samuelsson B (1964). Metabolism of prostaglandin El in the guinea pig lung: The structure of two metabolites. J Biol Chem 239:4097–4102Google Scholar
  3. Battaille R, Chappard D, Alexandre C, Dessauw P, Sany J (1986) Interest of bone histomor-phomeric analysis in monoclonal gammopathy. Br J Cancer 53:805–810CrossRefGoogle Scholar
  4. Beliel OM, Singer FR, Coburn JW (1973). Prostaglandins: effect on plasma calcium concentration. Prostaglandins 3:237–241PubMedCrossRefGoogle Scholar
  5. Bertolini DR, Nedwin GE, Brown TS, Smith DD, Mundy GR (1986). Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:576–578CrossRefGoogle Scholar
  6. Body JJ, Dumon JC, Gilbert F, Nejai S, Fernandez G (1989) Increased production of TNF alpha in tumor-associated hypercalcaemia. J Bone Miner Res 4 (Suppl):s253 (abstract)Google Scholar
  7. Bon jour JP, Phillipe J, Guelpa G, Bisetti A, Rizzoli R, Jung A, Rosini S, Kanis JA (1988) Bone and renal components in intravenous hypercalcemia of malignancy and response to a single infusion of clodronate. Bone 9:123–130CrossRefGoogle Scholar
  8. Boonekamp PM, Lowik CWGM, van der Wee Pals LJA, van Wijk-van Lennep MML, Thesing CW, Bijvoet OLM (1987). Enhancement of the inhibitory action on the transformation of osteoclast precursors into bone resorbing cells after demethylation of the amino group. Bone Miner 2:39–42Google Scholar
  9. Bounameaux H, Schifferli J, Montani JP, Jung A, Chatelanat F (1983) Renal failure associated with intravenous diphosphonates. Lancet i:471Google Scholar
  10. Boyd JC, Ladenson JH (1984). Value of laboratory tests in the differential diagnosis of hypercalcaemia. Am J Med 77:863–872PubMedCrossRefGoogle Scholar
  11. Brenner DE, Harvey HA, Lipton A, Demers L (1982) A study of prostaglandin E2, parathormone and response to indomethacin in patients with hypercalcemia of malignancy. Cancer 49:556–561PubMedCrossRefGoogle Scholar
  12. Breslau NA, McGuire JL, Zerwekh JE, Frenkel EP, Pak CYC (1984) Hypercalcaemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann Intern Med 100:1–7PubMedGoogle Scholar
  13. Breuer RI, LeBauer J (1967). Caution in the use of phosphates in the treatment of severe hypercalcemia. J Clin Endocrinol 27:695–698CrossRefGoogle Scholar
  14. Bringhurst FR, Bierer BE, Godeau F, Neyhard N, Varner V, Segre GV (1986) Humoral hypercalcemia of malignancy: release of a prostaglandin-stimulating bone resorbing factor in vitro by human transitional carcinoma cells. J Clin Invest 77:456–464PubMedCrossRefGoogle Scholar
  15. Brown JH, Kennedy BJ (1965). Mithramycin in the treatment of disseminated testicular neoplasms. N Engl J Med 272:111–118PubMedCrossRefGoogle Scholar
  16. Budayr AA, Halloran BP, King JC, Diep D, Nissenson RA, Strewler GJ (1989) High levels of parathyroid hormone-like protein in milk. J Bone Miner Res 4 (Suppl):sl38 (abstr).Google Scholar
  17. Burtis WJ, Brady TG, Wu TL, Ersbak J, Stewart AF (1989). Rapid immunoradiometric assay (IRMA) for parathyroid hormone-like protein (PTHLP). J Bone Miner Res 4 (Suppl):s310 (abstr)Google Scholar
  18. Chapuy MC, Meunier PJ, Alexandre C (1980). Effects of disodium dichloromethylene diphosphon-ate on hypercalcemia produced by bone metastases. J Clin Invest 65:1243–1247PubMedCrossRefGoogle Scholar
  19. Coleman RE, Rubens RD (1987) 3-amino-l, l-hydroxypropylidene bisphosphonate (APD) for hypercalcaemia of breast cancer. Br J Cancer 56:465–469PubMedCrossRefGoogle Scholar
  20. Danks JA, Ebeling PR, Hayman J, Chou ST, Moseley JM, Dunlop J, Kemp BE, Martin TJ (1988) Parathyroid hormone-related protein of cancer: immunohistochemical localisation in cancers and in normal skin. J Bone Miner Res 4:273–278CrossRefGoogle Scholar
  21. Davies M, Hayes ME, Mawer EB, Lumb GA (1985) Abnormal vitamin D metabolism in Hodgkin’s lymphoma. Lancet ii: 1186–1188Google Scholar
  22. Duff GW (1989). Peptide regulatory factors in non-malignant disease. Lancet i: 1432–1435Google Scholar
  23. Durie BJM, Salmon SE, Mundy GR (1981). Relation of osteoclast activating factor production to the extent of metastatic bone disease in myeloma. Br J Cancer 47:21–30Google Scholar
  24. Fetchick DA, Bertolini DR, Sarin PS, Weintraub ST, Mundy GR, Dunn JD (1986). Production of 1,25 dihydroxyvitamin D by human T-cell lymphotrophic 1 virus transformed lymphocytes. J Clin Invest 78:592–596PubMedCrossRefGoogle Scholar
  25. Fisken RA, Heath DA, Bold AM. Hypercalcaemia -a hospital survey. OJ Med 1980;196:405–418Google Scholar
  26. Fleish H (1982). Bisphosphonates: mechanisms of action and clinical applications. In: Peck WA (ed) Bone and mineral research, vol 1. Amsterdam, Excerpta Medica, pp 319–357Google Scholar
  27. Franklin RB, Tashjian AH (1975). Intravenous infusions of prostaglandin E2 raises plasma calcium in the rat. Endocrinology 97:240–243PubMedCrossRefGoogle Scholar
  28. Fried RM, Voelkel EF, Rice RH, Levine L, Gaffney EV, Tashjian AH (1989) Two squamous cell carcinomas not associated with humoral hypercalcemia produce a potent bone resorption stimulating factor which is interleukin-1 alpha. Endocrinology 125:742–751PubMedCrossRefGoogle Scholar
  29. Fukomoto S, Matsumoto T, Ikeda K, et al. (1988) Clinical evaluation of calcium metabolism in adult T-cell leukaemia/lymphoma. Arch Intern Med 148:921–925CrossRefGoogle Scholar
  30. Fukomoto S, Matsumoto T, Yamoto H et al. (1989) Supression of serum 1,25 dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25-dihydroxyvitamin D production. Endocrinology 124:2057–2062CrossRefGoogle Scholar
  31. Gallacher SJ, Ralston SH, Patel U, Boyle IT (1989) Side effects of Pamidronate. Lancet ii:42–43Google Scholar
  32. Garrett IR, Durie BJM, Nedwin GE et al. (1987) Production of lymphotoxin -a potent bone resorbing cytokine -by cultured myeloma cells. N Engl J Med 317:526–532PubMedCrossRefGoogle Scholar
  33. Goltzman D, Stewart AF, Broadus AE (1981). Malignancy-associated hypercalcemia: evaluation with a cytochemical bioassay for parathyroid hormone. J Clin Endocrinol Metab 53:899–904PubMedCrossRefGoogle Scholar
  34. Gowen M, Wood DD, Ihrie EJ, McGuire MKB, Russell RGG (1983) An interleukin-1 like factor stimulates bone resorption in vitro. Nature 306:378–380PubMedCrossRefGoogle Scholar
  35. Greaves M, Ibbotson KJ, Atkins D, Martin TJ (1980) Prostaglandins as mediators of bone resorption in renal and breast tumours. Metabolism 58:201–210Google Scholar
  36. Hasling C, Charles P, Mosekilde L (1987) Etidronate disodium in the management of malignancy-associated hypercalcemia. Am J Med 82 (Suppl 2A):51–54PubMedCrossRefGoogle Scholar
  37. Henderson JE, Shustik C, Kremer R, Rabbani SA, Hendy GN, Goltzman D (1989) Immunoreactive parathyroid hormone-like peptide in the plasma of patients with malignancy and with hyperparathyroidism. J Bone Miner Res 4 (Suppl):s323 (abstr)Google Scholar
  38. Herbert LA, Lemann J, Peterson JR, Lennon EJ (1966) Studies of the mechanism by which phosphate lowers serum calcium concentration. J Clin Invest 45:1866–1894Google Scholar
  39. Horiuchi H, Caulfield MP, Fisher JE et al. (1987) A similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 238:1566–1568PubMedCrossRefGoogle Scholar
  40. Hosking DJ, Cowley A, Bucknall CA (1981) Rehydration in the treatment of severe hypercal caemia. O J Med 200:473–478Google Scholar
  41. Hosking DJ (1983). Disequilibrium hypercalcaemia. Br Med J 286:326–327CrossRefGoogle Scholar
  42. Hosking DJ, Gilson D (1984) Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. Q J Med 211:359–369Google Scholar
  43. Ikeda K, Mangin M, Dreyer B et al. (1988) Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNA’s from a variety of human an animal tumors associated with hypercalcaemia of malignancy. J Clin Invest 81:2010–2014PubMedCrossRefGoogle Scholar
  44. Isales C, Carcangui ML, Stewart AF (1987) Hypercalcaemia in breast cancer: a re-evaluation. Am J Med 82:1143–1147PubMedCrossRefGoogle Scholar
  45. Jung A (1972) Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Ann Intern Med 29:923–930Google Scholar
  46. Kanis JA, Urwin GH, Gray RES et al. (1987) Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med 82 (Suppl 2A):55–70PubMedCrossRefGoogle Scholar
  47. Kemp BE, Moseley JM, Rodda CP et al. (1987) Parathyroid hormone-related protein of malignancy: active synthetic fragments. Science 237:1568–1570CrossRefGoogle Scholar
  48. Klein DC, Raisz LG (1970) Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology 80:1436–1440CrossRefGoogle Scholar
  49. Kukreja SC, Shavin DH, Wimbiscus S, Ebeling PR, Wood WI, Martin TJ (1988) Antibodies to parathyroid hormone-related protein lower serm calcium in athymic mouse models of malignancy-associated hypercalcemia. J Clin Invest 82:1798–1802PubMedCrossRefGoogle Scholar
  50. Lafferty FW (1966) Pseudohyperparathyroidism. Medicine 45:247–260PubMedCrossRefGoogle Scholar
  51. Martin TJ, Suva LJ (1988) Parathyroid hormone-related protein: a novel gene product. Bailliere’s Clin Endocrinol Metab 2:1003–1029CrossRefGoogle Scholar
  52. McDonnell GD, Dunstan CR, Evans RA et al. (1982) Quantitative bone histology in the hypercalcaemia of malignant disease. J Clin Endocrinol Metab 55:1066–1072CrossRefGoogle Scholar
  53. Meredino TJ, Insogna KL, Milstone LM, Broadus AE, Stewart AF (1986). A parathyroid hormone-like protein from cultured human keratinocytes. Science 231:388–390CrossRefGoogle Scholar
  54. Minkin C, Fredericks RS, Porkess S et al. (1981) Bone resorption and humoral hypercalcemia of malignancy: stimulation of bone resorption in vitro by tumour extracts is inhibited by prostaglandin synthetase inhibitors. J Clin Endocrinol Metab 53:941–947PubMedCrossRefGoogle Scholar
  55. Morton AR, Cantrill JA, Craig AE, Howell A, Davies M, Anderson DC (1988) Single versus daily intravenous aminohydroxypropylidene bisphosphonate (APD) for the hypercalcaemia of malignancy. Br Med J 296:811–814CrossRefGoogle Scholar
  56. Moseley JM, Kubota M, Diefenbach-Jagger H et al. (1987) Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA 84:5048–5052PubMedCrossRefGoogle Scholar
  57. Motokura T, Fukomoto S, Takahashi S, Watanabe T, Matsumoto T, Igarashi T, Ogata E (1988) Expression of parathyroid hormone-related protein in a human T-cell lymphoma lymphotrophic virus type 1 infected cell. Biochem Biophys Res Comm 154:1182–1188PubMedCrossRefGoogle Scholar
  58. Mudde AH, Van der Berg H, Breedveld FC, Nijweide PJ, Papapoulos SE, Bijvoet OLM (1985) Lymphoma-associated hypercalcaemia. In vitro demonstration of 1,25 dihydroxyvitamin D3 production. Calcif Tissue Int 38 (Suppl):s36 (abstr)Google Scholar
  59. Mundy GR, Luben RA, Raisz LG, Oppenheim JJ, Buell DN (1974) Bone resorbing activity in supernatants from lymphoid cell lines. N Engl J Med 290:867–871PubMedCrossRefGoogle Scholar
  60. Mundy GR, Martin TJ (1982) Hypercalcaemia of malignancy: pathogenesis and management. Metabolism 31:1247–1277PubMedCrossRefGoogle Scholar
  61. Mundy GR, Ibbotson KJ, D’Souza SM, Simpson EL, Jacobs JW, Martin TJ (1984) The hypercalcemia of cancer: clinical implications and pathogenic mechanisms. N Engl J Med 310:1718–1726PubMedCrossRefGoogle Scholar
  62. Mundy GR, Ibbotson KJ, D’Souza SM (1985) Tumor products and the hypercalcemia of malignancy. J Clin Invest 76:391–394PubMedCrossRefGoogle Scholar
  63. Nussbaum SR, Mallette L, Gagel R et al. (1989) Single dose treatment of hypercalcemia of malignancy with aminohydroxypropylidene bisphosphonate (APD). J Bone Miner Res 4 (Suppl):s313 (abstr)Google Scholar
  64. Patt LM, Houck JC (1983) Role of polypeptide growth factors in normal an abnormal growth. Kidney Int 23:603–610PubMedCrossRefGoogle Scholar
  65. Percival RC, Yates AJP, Gray RES et al. (1985) Mechanisms of hypercalcaemia in carcinoma of the breast. Br Med J 291:776–779CrossRefGoogle Scholar
  66. Perlia CP, Gubisch NJ, Wolter J, Edelberg D, Dederick MM, Taylor SG (1970) Mithramycin treatment of hypercalcemia. Cancer 1970; 25:389–394PubMedCrossRefGoogle Scholar
  67. Raisz LG, Simmons HA, Sandberg AL, Canalis E (1983). Direct stimulation of bone resorption by epidermal growth factor. Endocrinology 23:603–610Google Scholar
  68. Ralston SH (1987) The pathogenesis of humoral hypercalcaemia of malignancy. Lancet ii: 1443–1446Google Scholar
  69. Ralston SH, Fogelman I, Gardner MD, Boyle IT (1982) Hypercalcaemia and metastatic bone disease: is there a causal link? Lancet i:903–905Google Scholar
  70. Ralston SH, Fogelman I, Gardner MD, Boyle IT (1984a) Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. Br Med J 288:812–813CrossRefGoogle Scholar
  71. Ralston SH, Cowan RA, Robertson AG, Gardner MD, Boyle IT (1984b) Circulating vitamin D metabolites »and hypercalcaemia of malignancy. Acta Endocrinol 106:556–563PubMedGoogle Scholar
  72. Ralston SH, Fogelman I, Gardner MD, Dryburgh FJ, Cowan RA, Boyle IT (1984c) Hypercalcaemia of malignancy: evidence for a non-parathyroid humoral mediator with an effect on renal tubular calcium handling. Clin Sci 66:187–191PubMedGoogle Scholar
  73. Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT (1985) Comparison of aminohydroxypropylidene diphosphonate, mithramycin and corticosteroids/calcitonin in treat ment of cancer-associated hypercalcaemia. Lancet ii:907–910Google Scholar
  74. Ralston SH, Alzaid AA, Gardner MD, Boyle IT (1986) Treatment of cancer-associated hypercalcaemia with combined aminohydroxypropylidene bisphosphonate and calcitonin. Br Med J 292:1549–1550CrossRefGoogle Scholar
  75. Ralston SH, Cowan RA, Gardner MD, Fräser WD, Marshall E, Boyle IT (1987) Comparison of intestinal calcium absorption and circulating 1,25-dihydroxyvitamin D levels in malignancy-associated hypercalcaemia and primary hyperparathyroidism. Clin Endocrinol 26:281–291CrossRefGoogle Scholar
  76. Ralston SH, Alzaid AA, Gallacher SJ, Gardner MD, Cowan RA, Boyle IT (1988) Clinical experi ence with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia. Q J Med 258:825–834Google Scholar
  77. Ralston SH, Boyce BF, Cowan RA, Gardner MD, Fräser WD, Boyle IT (1989a) Contrasting mechanisms of hypercalcemia in patients with early and advanced humoral hypercalcemia of malignancy. J Bone Miner Res 4:103–111PubMedCrossRefGoogle Scholar
  78. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT (1990) Cancer associated hypercalcaemia; morbidity and mortality: experience in 126 patients. Ann Intern Med 112:499–504PubMedGoogle Scholar
  79. Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fräser WD, Cowan RA, Boyle IT (1989b) Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet ii: 1180–1183Google Scholar
  80. Ringerberg OS, Ritch PS (1987) Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients. Clin Ther 9:1–7Google Scholar
  81. Robertson RB, Baylink DJ, Metz SA, Cummings KB (1976) Plasma prostaglandin E in patients with cancer with and without hypercalcaemia. J Clin Endocrinol Metab 43:1330–1335PubMedCrossRefGoogle Scholar
  82. Rodan G, Insogna KL, Vignery A et al. (1983) Factors associated with humoral hypercalcaemia of malignancy stimulate adenylate cyclase in osteoblastic cells. J Clin Invest 72:1151 -1515CrossRefGoogle Scholar
  83. Rodda CP, Kubota M, Heath JA et al. (1988) Evidence for a novel parathyroid hormone-related protein in fetal lamb parathyroid glands and sheep placenta: Comparisons with a similar protein implicated in humoral hypercalcaemia of malignancy. J Endocrinol. 117:261–271PubMedCrossRefGoogle Scholar
  84. Rosenthal N, Insognal KL, Godsall JW, Smaldone L, Waldron JA, Stewart AF (1985) Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcaemia. J Clin Endocrinol Metab 60:29–33PubMedCrossRefGoogle Scholar
  85. Sabatini M, Boyce BF, Aufdemorte T, Bonewald L, Mundy GR (1988) Infusions of recombinant interleukin-1 alpha and beta cause hypercalcemia in normal mice. Proc Natl Acad Sci USA 85:5235–5239PubMedCrossRefGoogle Scholar
  86. Sato K, Fuji Y, Kasono K, Tsushima T, Shizume K (1988) Production of interleukin-1 alpha and a parathyroid hormone-like factor by a squamous cell carcinoma of the oesophagus (EC-GI) derived from a patient with hypercalcemia. J Clin Endocrinol Metab 67:592–621PubMedCrossRefGoogle Scholar
  87. Sato K, Fuji Y, Kashara T et al. (1989) Treatment by anti-PTH related protein antibody and anti-interleukin-1 antibody of hypercalcemia in nude mice transplanted with squamous cell carcinoma producing PTHrP and IL-1 alpha. J Bone Miner Res 4 (Suppl):s310 (abstr)Google Scholar
  88. Seyberth HW, Segre GV, Morgan JL, Sweetman BJ, Potts JT, Oates JA (1975) Prostaglandins as mediators of hypercalcemia in certain types of cancer. N Engl J Med 273:1278–1283CrossRefGoogle Scholar
  89. Shigeno C, Yamamoto I, Dokoh S et al. (1985) Identification of l,24R-dihydroxyvitamin D3-like bone resorbing lipid in a patient with cancer-associated hypercalcemia. J Clin Endocrinol Metab 61:761–768PubMedCrossRefGoogle Scholar
  90. Simpson EL, Mundy GR, D’souza SM, Ibbotson KJ, Bockman R, Jacobs JW (1983) Absence of parathyroid hormone messenger RNA in non-parathyroid tumors associated with hypercalcemia. N Engl J Med 309:325–330PubMedCrossRefGoogle Scholar
  91. Skrabanek P, McPartlin D, Powell DM (1980) Tumour hypercalcaemia and ectopic hyperparathyroidism. Medicine 59:262–282PubMedCrossRefGoogle Scholar
  92. Sleeboom HP, Bijvoet OLM, Van Oosteroom AT, Gleed JH, O’Riordan JLH (1983) Comparison of intravenous (3-amino-l-hydroxypropylidene)-l, 1-bisphosphonate and volume repletion in tumour induced hypercalcaemia. Lancet ii:239–243Google Scholar
  93. Stewart AF, Horst RL, Deftos LJ, Cadman EC, Lang R, Broadus AE (1980) Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and non-humoral groups. N Engl J Med 303:1377–1383PubMedCrossRefGoogle Scholar
  94. Stewart AF, Vignery A, Silvergate A et al. (1982) Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 55: 219–227PubMedCrossRefGoogle Scholar
  95. Stewart AF, Insogna KL, Goltzman D, Broadus AE (1983) Identification of adenylate cyclase stimulating activity in extracts of tumor associated with humoral hypercalcemia of malignancy. Proc Natl Acad Sci USA 80:1454–1459PubMedCrossRefGoogle Scholar
  96. Stewart AF, Insogna KL, Goltzman D, Broadus AE. Suva LJ, Winslow GA, Moseley JM et al. (1987) A parathyroid hormone-related protein implicated in malignant hypercalemia: cloning and expression. Science 237:893–896CrossRefGoogle Scholar
  97. Strewler GJ, Williams RD, Nissenson RA (1983) Human renal carcinoma cells produce hypercalcaemia in the nude mouse and a novel protein recognised by parathyroid hormone receptors. J Clin Invest 71:769–774PubMedCrossRefGoogle Scholar
  98. Strewler GJ, Stern PH, Jacobs JW et al. (1987) Parathyroid hormone-like protein from renal carcinoma cells: structural and functional homology with parathyroid hormone. J Clin Invest 80:1803–1807PubMedCrossRefGoogle Scholar
  99. Suki WN, Yium JJ, Von Minden M, Saller-Hebert C, Eknoyan C, Martinez-Maldonado M (1970) Acute treatment of hypercalcemia with furosemide. N Engl J Med 283:836–840PubMedCrossRefGoogle Scholar
  100. Suva LJ, Winslow GA, Moseley JM et al. (1987) A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237:893–896PubMedCrossRefGoogle Scholar
  101. Tashjian AH (1975). Tumor humors and the hypercalcemia of cancer. N Engl J Med 293:1317–1318PubMedCrossRefGoogle Scholar
  102. Tashjian AH, Levine L (1978). Epidermal growth factor stimulates prostaglandin production and bone resorption in cultured mouse calvariae. Biochem Biophys Res Comm 85:966–972PubMedCrossRefGoogle Scholar
  103. Tashjian AH, Voelkel EH, Lazzaro M et al. (1985) Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvariae. Proc Natl Acad Sci USA 82:4535–4538PubMedCrossRefGoogle Scholar
  104. Tashjian AH, Voelkel EF, Lloyd W, Derynck R, Winkler ME, Levine L (1986) Actions of growth factors on plasma calcium. J Clin Invest 78:1405–1409PubMedCrossRefGoogle Scholar
  105. Thallasinos N, Joplin GF (1968) Phosphate treatment of hypercalcaemia due to carcinoma. Br Med J iv:14–19CrossRefGoogle Scholar
  106. Thallasinos N, Joplin GF (1970) Failure of corticosteroid therapy to correct the hypercalcaemia of malignant disease. Lancet ii:537–539Google Scholar
  107. Thiebaud D, Jaeger PH, Jaquet AF, Burckhardt P (1986a) A single day treatment of tumour induced hypercalcaemia by intravenous aminohydroxypropylidene bisphosphonate. J Bone Miner Res 1:555–562PubMedCrossRefGoogle Scholar
  108. Thiebaud D, Portmann L, Jaeger P et al. (1986b) Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy. Bone 7:247–253PubMedCrossRefGoogle Scholar
  109. Tracey KJ, Vlassara H, Cerami A (1989). Cachectin/tumour necrosis factor. Lancet i: 1122–1126Google Scholar
  110. Travers MT, Barrett-Lee PJ, Berger U, et al. (1988) Growth factor expression in normal, benign and malignant breast tissue. Br Med J 296:1621–1624CrossRefGoogle Scholar
  111. Warrell RP, Israel R, Frisone M, Snyder T, Gaynor JJ, Bockman RS (1988) Gallium nitrate for acute treatment of cancer-related hypercalcemia. Ann Intern Med 108:669–674PubMedGoogle Scholar
  112. Warwick OH, Yendt ER, Olin JS (1961). The clinical features of hypercalcemia associated with malignant disease. J Canad Med Ass 23:719–723Google Scholar
  113. Wisneski LA, Croom WP, Silva OL, Becker KL (1978) Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther 24:219–222PubMedGoogle Scholar
  114. Wo G, Bonewald LF, Oreffo R, Chirgwin JM, Capony F, Rochefort H, Mundy GR (1989) Evidence that lysosomal procathepsin D secreted by human breast cancer cells activates osteoclasts. J Bone Miner Res 5:s322 (abstr)Google Scholar
  115. Yamamoto I, Kitamura N, Aoki J et al. (1987) Circulating 1,25 dihydroxyvitamin D concentrations in patients with renal cell carcinoma hypercalcaemia are rarely suppressed. J Clin Endocrinol Metab 64:175–179PubMedCrossRefGoogle Scholar
  116. Yamamoto I, Kawano M, Sone T, Iwato K, Shigeno C, Kuramoto A (1989) Production of interleukin-1 beta, a potent bone resorbing cytokine, by human myeloma cells. J Bone Miner Res 5:s254 (abstr)Google Scholar
  117. Yates AJP, Guttierez GE, Smolens P et al. (1988) Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption and bone metabolism in vivo and in vitro. J Clin Invest 81:932–938PubMedCrossRefGoogle Scholar
  118. Yonenda T, Alsina M, Chavez J, Bonewald L, Mundy GR (1989) Hypercalcemia in a human tumor is due to tumor necrosis factor production by host immune cells. J Bone Miner Res 4 (Suppl):s324 (abstr)Google Scholar
  119. Yoshimito K, Yamasaki R, Sakai H et al. (1989) Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinal Metab 68:976–981CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1991

Authors and Affiliations

  • S. H. Ralston

There are no affiliations available

Personalised recommendations